Prescription drug · ANDA
Dichlorphenamide NDC 13668-676
Dichlorphenamide 50 mg/1 · Tablet · Oral · Torrent pharmaceuticals limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 13668-676-01 | 13668067601 | 100 TABLET in 1 BOTTLE (13668-676-01)Marketed from Dec 29, 2022 | |
| 13668-676-30 | 13668067630 | 30 TABLET in 1 BOTTLE (13668-676-30)Marketed from Dec 29, 2022 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Dichlorphenamide
- Generic name (nonproprietary)
- dichlorphenamide
- Active ingredients
- Dichlorphenamide — 50 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215924
- Marketing start
- Listing expires
- Other FDA classes
- Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
- Identifiers
- Product ID 13668-676_1d0520f1-bf08-4def-a715-2ab45a18393eSPL ID 1d0520f1-bf08-4def-a715-2ab45a18393eSPL set ID 64bf0c71-2113-47dc-8ce5-7fe535e558dcRxCUI 197594UNII VVJ6673MHYUPC 0313668676303
- Pharmacologic class
- Carbonic Anhydrase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N413668067601followed by a unit qualifier and the quantityPackage 13668-0676-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Dichlorphenamide tablets are indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Dichlorphenamide tablets are an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 215924
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ormalvidichlorphenamide | Dichlorphenamide 50 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd. | 70709-085 |